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Abstract - Jejunal perfusion of cimetidine resulted in the appearance of lumenal cimetidine sulfoxide in both rata and 
humans. In the rat, heal perfusion yielded negligible sulfoxide metabolite as compared with that of the jejunum. 
Jejunal co-perfusion of an anionic-exchange inhibitor, 4,4’-diisothiocyanostilbene-2,2’-disulfonic acid, blocked the 
appearance of drug sulfoxide, and methionine co-perfusion yielded concentration-dependent inhibition of lumenal 
cimetidine sulfoxide. Intravenous injection of high concentrations of cimetidine sulfoxide did not produce detectable 
lumenal metabolite levels during jejunal perfusion of drug-tiee buffer, providing in situ evidence that lumenal 
metabolite is generated by the small intestine. Tbe extent of the appearance of lumenal sulfoxide was significantly 
greater for cimetidine than for the other three marketed H2-antagonists in rat jejunum. Variable intestinal clearance of 
this extensively prescribed class of therapeutic agents may contribute to their absorption variability. 
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The oral administration of H2-receptor antagonists 
has been of therapeutic utility in the treatment of 
gastric and duodenal ulcers, as well as 
gastroesophageal reflux disease. There are currently 
four H7-antaaonist nrescrintlon drugs on the U.S. 
market: cim&dme,* m&dine, fa&otidine and 
nizatidine. These drugs are characterized by 
incomplete and variable absorption, resulting in drug 
plasma level variability. The incomplete absorption 
has been attributed to the poor intestinal membrane 
permeation (1) of these weakly basic drugs, which are 
ionized at intestinal DH. The counlina of variable 
small intestinal reside&e time and limit&l membrane 
permeation is responsible for much of the absorption 
variability (2). 
In the course of an in situ rat jejunal perfusion study 
investigating the effects of mucosal microclimate pH 
on cimetidine ionization and absorption (3), a 
substantial quantity of metabolite was detected by 
HPLC analysis of the exiting perfusate. Confirmation 
of metabolite identity and subsequent characterization 
of H?-antagonist intestinal clearance are the subjects 
of this report. The metabolite was observed to co- 
elute with standard cimetidine sulfoxide. and 
identification was later verified by mass spectrometry. 
Cimetidine jejunal perfusions in two human subjects 
also yielded the sulfoxide metabolite in the lumenal 
contents. 
Drug sulfoxidation in animal small intestinal 
micr&omal preparations was first documented for 
nhenothiazines in 1977 (4). and intestinal 
‘sulfoxidation of albendazole, G’anthelmintic drug, 
has been reported recently (5). While phase II 
metabolism is more commonly cited as an intestinal 
clearance mechanism (6), phase I cyclosporin 
metabolism in rat (7) and human (8) intestine has 
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been shown to influence oral cyclosporin absorption 
variability (9). 
In addition to a comparison of intestinal 
sulfoxidation of the commercially available H2- 
antagonists, this study provides preliminary 
information on regional and flow rate dependence of 
cimetidine sulfoxidation, as well as identification of 
inhibitors of metabolic clearance. 
Materials and Methods 
h4uteriuk Cimetidine, famotidine, ranitidine, DIDS, 
methionine, sodium and potassium chloride, MES 
buffer and PEG 4000 were obtained from the Sigma 
Chemical Co. (St. Louis, MO). Carbon-14 labeled 
PEG 4000 was obtained from New England Nuclear, 
Dupont (Wilmington, DE). Nizatidiie, cimetidine 
sulfoxide and famotidine sulfoxide were gifts from 
Eli Lilly, SmithKline Beecham and the Yr&anouchi 
Pharmaceutical Co., respectively. 
Rat perjisions. Experimental details of the single- 
pass in situ rat intestinal perfusion technique have 
been reported previously (1). A midline incision was 
made in anesthetized rats; inlet Tygon tubing was 
inserted into the jejunum 10 cm distal to the ligament 
of Treitz. and an outlet tube was inserted 6-8 cm 
distal to the inlet. In some studies, a second perfusion 
was carried out in the ileum with the outlet tubing 2 
cm proximal to the ileocecal junction and the inlet 
tube 6-8 cm proximal to the outlet. Iso-osmotic 
perfusion solutions containing 5 mM potassium 
chloride and 135 mM sodium chloride were adjusted 
to pH 6.5 using 10 mM MES buffer. Some of the 
ileal perfusions were performed at pH 7.5 using 
HEPES buffer. The non-absorbable marker, 0.01% 
PEG 4000 traced with [*4C]PEG 4000 (specific 
activity 3.2 x lo6 dpm/pmol), was included to correct 
drug and metabolite concentration for intestinal water 
tra&ort. Perfusion H2-antagonist concentrations 
were 0.4 mM, consistent with projected jejunal 
concentrations from a typical human famotidine oral 
dose (40 mg) taken with 8 ounces of fluid (0.5 mg in 
a 2-mL gastric fluid load in rat). Cimetidine 
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perfusions were also performed at 4 mM, consistent 
with projected jejunal concentrations from a typical 





of the in the 
40 of Treitz. 
of the 
in place, a tube-mounted 
balloon was inflated to 20 to 
provide of the 
of drug a 
tubing nort iust distal to 
a 
suction port approximately 50 cm distal to the of 
perfusion at -time 10 min 
of oerfusion UD to 1 hr. Measurements 
of low trypsin activity \;ere used to document 
effective occlusion. Trypsin was measured via a 
titrimetric method using para-tosyl-L-arginine methyl 
ester as a substrate (10). PEG 4000 was included as 
a non-absorbable marker so that drug and metabolite 
concentrations could be corrected for intestinal fluid 
absorption/secretion. PEG 4000 concentrations were 
assessed by a turbidimetric measurement (11). 
Measurement of drug and metabolite. Pet&ate 
concentrations of drug and metabolite were 
determined from standard curves made in blank 
perfusate. Neither drug oxidation nor metabolite 
reduction was observed in standard solutions. Results 
are reported from a reverse phase assay. An aqueous 
mobile phase (made at pH 3 with phosphoric acid) 
containing 3.5% acetonitrile and 1% triethylamine 
was pumped through an RP-18 column at 1.4 
mL/min. Detection of the sulfoxide at 3 min and drug 
at 8.5 min was carried out at 228 nm. Co-elution of 
standard sulfoxide with metabolite was also 
confirmed with normal phase and ion-pairing HPLC 
assays. The metabolite assay limit of detection was 
50 nM. 
Metabolite identtfkation. Rat and human perfusate 
metabolite was identified initially as the sulfoxide, 
since spiking perfusate samples with standard 
cimetidine sulfoxide and famotidine sulfoxide showed 
that the suspected metabolite co-eluted with standard. 
MS analyses were carried out on HPLC fraction- 
collected single rat and human cimetidine perfusate 
samples and compared with standard cimetidine and 
standard cimetid’me sulfoxide. Analyses were 
uerformed utilizinrr an Autospec Ultima-Q hybrid 
mass spectrometer-(VG Analy&al Ltd., Manchester, 
UK) of EBEqQ geometry. Ionization was by LSIMS, 
using cesium ions with energies of 20 keV for the 
primary beam. The liquid matrix was 3-nitrobenzyl 
alcohol. One microliter of HPLC fraction was applied 
to the probe. These analyses confirmed the 
identification of cimetidine sulfoxide as the 
metabolite HPLC peak from rat and human jejunal 
cimetidine perfusions. 
Results and Discussion 
Comparison of rat jejunal H2-antagonist 
sulfoxidation. The lumenal appearance of H2- 
antagonist sulfoxide metabolite was quantitated as the 
molar ratio of sulfoxide to parent drug in the exiting 
perfusate. The results (normalized for the length in 
centimeters of the perfused intestinal segment) are 
displayed in Fig. 1. Standard sulfoxide metabolites 
were only available for cimetidine and famotidine. 
Peaks eluting at times equivalent to cimetidine and 
famotidine sulfoxide standards from nizatidine and 
ranitidine perfusions were treated as sulfoxide 
metabolite. 
cimetidine nizatidine ranitidine 
Treatment 
Fig. 1. Mean molar percent sulfoxide metabolite (2 
SEM) for each drug, shown per centimeter of 
perfised jejunal length. Perfirsions were performed at 
pH 6.5 and a flow rate of 0.12 mumin. Inlet drug 
concentrations were performed at 0.4 mM for each 
H2-antagonist with at least 4 animals per drug. 
* Significantly dtflerent from cimetidine at the 
P=O.O5 level by Student’s t-test. 
Cimetidine sulfoxide: Dependence on route of 
administration, intestinal region, perfusion 
concentration and flow rate. Neither cimetidine nor 
the sulfoxide metabolite was observed in exiting 
jejunal perfusate of drug-free buffer following 
intravenous administration of 1 mL cimetidine 
sulfoxide (4 mM). This result suggests that 
metabolite from drug perfusion is of intestinal rather 
than systemic origin. 
Considerably less sulfoxidation was observed in rat 
ileum as compared with jejunal cimetidine perfusions 
(Fig. 2). At a perfusion flow rate of 0.19 mL/min, the 
percent of jejunal cimetidine sulfoxidation was not 
different over a IO-fold concentration range 
(calculated on the basis of the typical oral dose for 
this class of agents). 
J.w J.q.C J.0.C J.Q.C I.q.c 
Treatment 
Fig. 2. Percent of cimetidine sulfoxide appearing in 
exiting per&sate as a function of intestinal region 
(J=jejunum, I=ileum), perfusion jlow rate (q=O.IZ 
mL/min, Q=O.19 mumin) and drug concentration 
(C=4 mM, c=O.4 mh@ * Significantly differentjFom 
Jq,c at the P=O.O5 level by Student’s t-test. 
Rapid immunizations 231 
Decreasing the perfusion flow rate to 0.12 mL./min 
significantly increased the percentage of jejunal 
cimetidine sulfoxidation (Fig. 2). These results 
suggest that the extent of H2-antagonist sulfoxidation 
will be a strong function of drug residence time 
coupled to clearance capacity in upper and lower 
small intestine. It is projected that variable regional 
residence times contribute to the drug plasma level 
double peaks (two drug blood concentration maxima 
following oral administration) observed in clinical 
practice. 
Human j~unal cimetidine su~oxidation, To assess 
the clinical relevance of these findings, p~lirn~ 4 
mM cimetidine perfusions were camed out in two 
human subjects at 10 mLJmin over 50 cm of jejunum. 
The nerfusate content of cimetidine sulfoxide was 6% 
in the first subject and 3% in the second subject. 
While this is considerablv less sulfoxidation than 
observed in rat jejunum, siower perfusion flow rates 
at a lower cimetidine concentration are proiected to 
produce a greater extent of lumenal metabblite. 
Inhibitors of cimetidine sulfoxide awwearance in the 4. 
rat jeiunal lumen. As these”studies&&ere undertaken 
originally to investigate the effect of mucosal 
microclimate DH on variable absorntion of cimetidine. 
amiloride and DIDS were emnlo;ed as inhibitors of 
mucosal sodium-proton and ~~O~de-bi~~Mte 
exchanee (3). Inclusion of 100 uM DIDS in 0.4 mM 
cimetid&e’~eri?rsions reduced the levels of an early 
eluting peak later established as the sulfoxide 
metabolite (Fig. 3). 
Subsequent to identification of cimetidine 
sulfoxidation, notential inhibitors were selected from 
products of intestinal sulfur-containing amino acid 
metabolism. Cimetidine co-perfusion with taurine 
and replacement of perfusate sodium chloride with 
equal molar sodium sulfate failed to inhibit cimetidine 
dfoxide appearance in the jejunal hnnen (data not 
shown). Co-nerfusion of 0.4 mM cimetidine with 2.5 
mM glutathione reduced the appearance of cimetidine 
sulfoxide in the rat jejunal lumen. Co-perfusion of 
methionine produced a ~oncen~tion-de~ndent 
reduction in lumenal cimetidine sulfoxide (Fig. 3). 
control 2.5mM 5mM S&TIM 2.5mM 1WuM 
M M M G 0 
Fig. 3. Percent of cimetidine sulfoxide appearing in 
rat jejunal lumen in the presence of co-per$sed 
inhibitors (D=DIDS, G=giutathione, M=methionine). 
Cimetidine perfirsate concentration: 0.4 mM; 
erosion flow rate: 0.12 mUmin.. ~Sign~~eantl~ 
dl~erent~om control at the P=O.O5 level by Student 
t-test. 
While the DIDS results suggest that metabolite 
export might be blocked, lumenal methionine 
sulfoxide was not detected from cimetidine w- 
perfusion with methionine. More mechanistic studies 
are in progress. 
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